CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
GW685698/GW642444drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00731822
NCT00731822Phase 2Completed
CompareCT.gov

Study HZC111348, a Repeat-dose Study of GW685698/GW642444 Inhalation Powder Versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

GlaxoSmithKline·interventional·Posted Aug 11, 2008·Updated Dec 8, 2016

In Brief

A Phase 2 clinical trial evaluating GW685698/GW642444 for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 60 participants across 9 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess the safety and efficacy of a single dosage strength of GW685698/GW642444 in subjects with Chronic Obstructive Pulmonary Disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesNorway, Sweden
Collaborators--

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 11, 2008
Enrollment StartAug 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.9 years ago

Interventions

GW685698/GW642444drug

GW685698/GW642444